GENinCode Shares Rise on FDA Filing for Heart Disease Test Kit
16 Agosto 2023 - 8:41AM
Dow Jones News
By Ian Walker
Shares of GENinCode rose 17% after the company said that it has
filed a premarket notification with the U.S. Food and Drug
Administration for its coronary heart disease risk assessment test
kit, Cardio inCode-Score.
Shares at 1106 GMT were up 2.0 pence at 13.50 pence.
The London-listed predictive genetics company said Wednesday
that approval will enable the expansion and commercial distribution
of the device in the U.S.
It expects to receive FDA approval for the device over the next
six months.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
August 16, 2023 07:26 ET (11:26 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Genincode (LSE:GENI)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Genincode (LSE:GENI)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024